- Home
- Primary Care
- Long-Acting Monoclonal Antibodies in RSV: Nirsevimab and Beyond

6d3 min read
Medical Article
Respiratory syncytial virus (RSV) is one of the most common causes of acute lower respiratory infections in children globally and contributes significantly to severe respiratory disease in elderly persons (1). Each year, RSV causes an estimated 3.6 million hospitalizations and approximately 100,000 deaths in children under 5 years of age (1,2). App

Long-Acting Monoclonal Antibodies in RSV: Nirsevimab and Beyond
13 Reached
Similar Content

ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes

Catheter Ablation for Atrial Fibrillation with HF
691 Reached

Female with History of Amenorrhoea
3094 Reached10 Comments11 Likes

Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes

Role and Importance of DHA in Cognitive Development
524 Reached1 Likes